Use of this information is subject to copyright laws and may require the permission of the owner of the information, as described in the ECHA Legal Notice.
EC number: 947-946-9
CAS number: -
purpose of this study was to determine the potential toxicity of the
test item when administered daily for at least 28 days via oral gavage
to male and female Sprague Dawley rats and to determine potential
reproductive and developmental toxicity.
six (48/sex) Sprague Dawley rats were randomly assigned to four groups
(12 animals/sex). Animals were administered control substance (peanut
oil) or the test item at 0, 100, 300, or 700 mg/kg once daily via oral
gavage for at least 28 days. Animals were subjected to a full gross
necropsy on Study Day (SD) 35 (F0 males), or Postnatal Day (PND) 13
(parturient F0 females and pups). Females that did not litter were
subjected to a full gross necropsy on SD 57.
evaluated during the study included mortality, physical examinations,
cageside observations, body weights, body weight changes, food
consumption, vaginal cytology, clinical pathology (clinical chemistry,
hematology, and coagulation), thyroid hormone (T4) analysis (males and
PND 13 pups only), gross pathology findings, absolute and relative organ
weights, and histopathology findings.
with the test item at doses ≥ 300 mg/kg had an effect on the liver.
Test-substance related hepatocellular hypertrophy correlated with
increased liver weight parameters and increases in hepatobiliary enzyme
(GGT and/or ALTi) activities. Thyroid follicular cell hypertrophy in
males at doses ≥ 100 mg/kg/day and females administered ≥ 300 mg/kg/day
was considered most likely secondary to changes in the liver.
Additionally, test substance-related changes in the non-glandular
stomach consisted of mucosal hyperplasia with erosion or ulceration was
observed in animals administered 700 mg/kg/day, mild mucosal hyperplasia
in one animal administered 300 mg/kg/day and minimal hyperkeratosis and
minimal neutrophilic inflammation in another animal administered 300
mg/kg/day. These changes may have been a systemic effect of the test
substance or secondary to direct irritation of the mucosa.
was no effect on mortality, physical examinations, cage-side
observations, body weights, food consumption, vaginal cytology, clinical
pathology (hematology, coagulation, and urinalysis), thyroid hormone
analysis (males and PND 13 pups), or gross pathology findings at all
dose levels evaluated.
repeat dose no adverse effect level (NOAEL) was considered to be 100
mg/kg/day due to adverse body weight changes, organ weight changes and
microscopic findings of hepatocellular hypertrophy.
Information on Registered Substances comes from registration dossiers which have been assigned a registration number. The assignment of a registration number does however not guarantee that the information in the dossier is correct or that the dossier is compliant with Regulation (EC) No 1907/2006 (the REACH Regulation). This information has not been reviewed or verified by the Agency or any other authority. The content is subject to change without prior notice.Reproduction or further distribution of this information may be subject to copyright protection. Use of the information without obtaining the permission from the owner(s) of the respective information might violate the rights of the owner.
Tato webová stránka používá cookies, aby se vám naše stránky používaly co nejlépe.
Welcome to the ECHA website. This site is not fully supported in Internet Explorer 7 (and earlier versions). Please upgrade your Internet Explorer to a newer version.
Do not show this message again